WallStSmart

Avadel Pharmaceuticals PLC (AVDL)vsTeva Pharma Industries Ltd ADR (TEVA)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Teva Pharma Industries Ltd ADR generates 6881% more annual revenue ($17.35B vs $248.52M). TEVA leads profitability with a 9.0% profit margin vs -0.0%. AVDL appears more attractively valued with a PEG of 0.07. TEVA earns a higher WallStSmart Score of 62/100 (C+).

AVDL

Hold

41

out of 100

Grade: D

Growth: 4.3Profit: 2.5Value: 8.3Quality: 5.5
Piotroski: 3/9Altman Z: -5.40

TEVA

Buy

62

out of 100

Grade: C+

Growth: 6.0Profit: 7.0Value: 7.3Quality: 4.8
Piotroski: 6/9Altman Z: 0.28
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

AVDLUndervalued (+70.6%)

Margin of Safety

+70.6%

Fair Value

$73.50

Current Price

$21.64

$51.86 discount

UndervaluedFair: $73.50Overvalued
TEVAUndervalued (+46.3%)

Margin of Safety

+46.3%

Fair Value

$63.92

Current Price

$35.73

$28.19 discount

UndervaluedFair: $63.92Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AVDL1 strengths · Avg: 10.0/10
PEG RatioValuation
0.0710/10

Growing faster than its price suggests

TEVA2 strengths · Avg: 9.5/10
EPS GrowthGrowth
72.2%10/10

Earnings expanding 72.2% YoY

Return on EquityProfitability
21.6%9/10

Every $100 of equity generates 22 in profit

Areas to Watch

AVDL4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
0.5%4/10

0.5% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

TEVA4 concerns · Avg: 3.0/10
P/E RatioValuation
26.9x4/10

Moderate valuation

Revenue GrowthGrowth
2.3%4/10

2.3% revenue growth

Free Cash FlowQuality
$-208.00M2/10

Negative free cash flow — burning cash

Altman Z-ScoreHealth
0.282/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : AVDL

The strongest argument for AVDL centers on PEG Ratio. PEG of 0.07 suggests the stock is reasonably priced for its growth.

Bull Case : TEVA

The strongest argument for TEVA centers on EPS Growth, Return on Equity.

Bear Case : AVDL

The primary concerns for AVDL are Revenue Growth, EPS Growth, Operating Margin.

Bear Case : TEVA

The primary concerns for TEVA are P/E Ratio, Revenue Growth, Free Cash Flow.

Key Dynamics to Monitor

AVDL profiles as a turnaround stock while TEVA is a value play — different risk/reward profiles.

AVDL carries more volatility with a beta of 1.63 — expect wider price swings.

TEVA is growing revenue faster at 2.3% — sustainability is the question.

AVDL generates stronger free cash flow (23M), providing more financial flexibility.

Bottom Line

TEVA scores higher overall (62/100 vs 41/100). AVDL offers better value entry with a 70.6% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Avadel Pharmaceuticals PLC

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Avadel Pharmaceuticals plc is a biopharmaceutical company in the United States. The company is headquartered in Dublin, Ireland.

Visit Website →

Teva Pharma Industries Ltd ADR

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic drugs, specialty drugs, and biopharmaceuticals in North America, Europe, and internationally. The company is headquartered in Petach Tikva, Israel.

Want to dig deeper into these stocks?